Thyrotoxicosis
Verified clinical guidelines and emergency management protocols.
Protocol Content
Navigation
THYROID STORM โ INDIA
EMERGENCY MANAGEMENT GUIDELINE
๐ For Healthcare Professionals Only | Not for Public Use
Scope: Recognition | Diagnosis | Emergency Management | ICU Care | Monitoring
Format: Stepwise, action-oriented
Note: This is a MEDICAL EMERGENCY with mortality of 10-30% even with treatment. Early recognition and aggressive management are critical.
๐ฐ SYMBOL LEGEND
| Symbol | Meaning |
| โ | Recommended / First-line |
| โ ๏ธ | Caution / Monitor |
| โ | Contraindicated / Avoid |
| ๐ | Drug name |
| ๐ฎ๐ณ | India-specific consideration |
| ๐ | Key point |
| โก๏ธ | Next step |
| ๐จ | Emergency / Critical |
SECTION 1: OVERVIEW
1.1 DEFINITION
๐จ Thyroid Storm (Thyrotoxic Crisis) = A life-threatening, decompensated state of severe thyrotoxicosis characterized by multi-organ dysfunction and high mortality.
1.2 KEY POINTS
| Point |
|
Medical emergency requiring ICU admission
|
|
Mortality 10-30% even with optimal treatment
|
|
Clinical diagnosis โ Do NOT wait for lab confirmation
|
| Biochemical severity does NOT correlate with clinical severity |
|
Rapid, aggressive, multimodal treatment is essential
|
|
Usually occurs in patients with pre-existing thyrotoxicosis
|
|
Almost always has an identifiable precipitant
|
1.3 PATHOPHYSIOLOGY
Mechanism
UNDERLYING THYROTOXICOSIS
(Often undiagnosed or undertreated)
โ
โผ
PRECIPITATING EVENT
(Infection, Surgery, Trauma, etc.)
โ
โผ
โโโโโโโโโโโโโดโโโโโโโโโโโโ
โ โ
โผ โผ
↑↑ Catecholamine ↑↑ Thyroid Hormone
Sensitivity Action/Release
โ โ
โโโโโโโโโโโโโฌโโโโโโโโโโโโ
โ
โผ
MULTI-ORGAN FAILURE
โข Cardiovascular collapse
โข CNS dysfunction
โข Hyperthermia
โข GI/Hepatic failure
โ
โผ
DEATH (if untreated)
Key Pathophysiological Features
| Feature | Mechanism |
|
Hyperthermia
|
↑↑ Metabolic rate; ↓ Heat dissipation |
|
Cardiovascular
|
↑↑ Chronotropy/Inotropy; Vasodilation; High-output failure |
|
CNS
|
Direct CNS effects; Hyperthermia; Cerebral hypoxia |
|
GI/Hepatic
|
Hypoperfusion; Direct toxic effects |
|
Adrenal
|
Relative insufficiency (↑ Cortisol clearance) |
SECTION 2: ETIOLOGY AND PRECIPITANTS
2.1 UNDERLYING CAUSES OF THYROTOXICOSIS
| Cause | Frequency |
|
Gravesโ disease
|
Most common (60-80%) |
| Toxic multinodular goiter | Common |
| Toxic adenoma | Less common |
| Drug-induced (Amiodarone) | Increasing |
| Thyroiditis | Rare to cause storm |
| TSH-secreting adenoma | Rare |
| Struma ovarii | Rare |
| Functioning thyroid cancer metastases | Very rare |
2.2 PRECIPITATING FACTORS
๐ Almost always an identifiable precipitant โ Search for it!
Common Precipitants
| Category | Precipitant |
|
Infection ๐จ
|
Most common (respiratory, UTI, sepsis) |
|
Surgery
|
Especially thyroid surgery in unprepared patient |
|
Trauma
|
Including burns |
|
Acute illness
|
MI, Stroke, PE, DKA |
|
Medication
|
ATD withdrawal; Amiodarone; Iodinated contrast |
|
Obstetric
|
Labor and delivery; Cesarean section; Preeclampsia |
Other Precipitants
| Category | Precipitant |
|
RAI therapy
|
Radiation thyroiditis (rare) |
|
Vigorous thyroid palpation
|
Rare |
|
Iodine load
|
Contrast media; Amiodarone |
|
Drugs
|
Sympathomimetics; Pseudoephedrine |
|
Stress
|
Emotional; Physical |
|
Poor compliance
|
ATD discontinuation |
|
Direct thyroid injury
|
Biopsy; Surgery |
India-Specific Precipitants
| Precipitant | Notes |
|
Infection
|
Remains most common; TB, Tropical infections |
|
Untreated/Undertreated hyperthyroidism
|
Common due to delayed presentation |
|
Non-compliance
|
Cost; Access issues |
|
Surgery in unprepared patient
|
Inadequate pre-operative preparation |
|
Iodinated contrast
|
Increasing CT use without screening |
SECTION 3: CLINICAL FEATURES
3.1 CARDINAL FEATURES
| Feature | Description |
|
๐จ Hyperthermia
|
Temperature > 38.5°C, often > 40°C |
|
๐จ Tachycardia
|
Out of proportion; HR > 140 bpm; Atrial fibrillation |
|
๐จ Altered mental status
|
Agitation → Delirium → Psychosis → Coma |
|
๐จ Cardiovascular dysfunction
|
AF, Heart failure, Shock |
3.2 SYSTEMIC FEATURES
Cardiovascular
| Feature | Mechanism |
|
Sinus tachycardia
|
HR > 140-160 bpm common |
|
Atrial fibrillation
|
Up to 30-40% |
|
High-output heart failure
|
↑ Cardiac demand |
|
Widened pulse pressure
|
↑ Systolic, ↓ Diastolic |
|
Hypotension / Shock
|
Late; Decompensation |
|
Angina
|
↑ Myocardial oxygen demand |
|
Cardiac arrest
|
Terminal event |
Central Nervous System
| Feature | Progression |
|
Agitation / Restlessness
|
Early |
|
Anxiety / Emotional lability
|
Early |
|
Tremor
|
Fine tremor exaggerated |
|
Delirium / Confusion
|
Moderate |
|
Psychosis
|
May be prominent |
|
Seizures
|
Severe |
|
Coma
|
Late; Poor prognosis |
Thermoregulation
| Feature | Notes |
|
Hyperthermia
|
Temperature 38.5-41°C |
|
Profuse sweating
|
Attempt to dissipate heat |
|
Warm, flushed skin
|
Vasodilation |
Gastrointestinal / Hepatic
| Feature | Notes |
|
Nausea / Vomiting
|
Common |
|
Diarrhea
|
May be severe; Contributes to dehydration |
|
Abdominal pain
|
May mimic acute abdomen |
|
Jaundice
|
Hepatic dysfunction; Poor prognosis |
|
Hepatomegaly
|
Congestion |
Other
| Feature | Notes |
|
Dehydration
|
Sweating, Diarrhea, Vomiting, Fever |
|
Weight loss
|
Pre-existing from thyrotoxicosis |
|
Goiter
|
Usually present; May have bruit |
|
Eye signs
|
If Gravesโ disease |
3.3 SYMPTOMS AND SIGNS COMPARISON
| Feature | Thyrotoxicosis | Thyroid Storm |
| Temperature | Normal/Slight ↑ |
> 38.5°C, often > 40°C
|
| Heart rate | 100-120 |
> 140-160
|
| Mental status | Normal/Anxious |
Altered (Delirium → Coma)
|
| Cardiac | Palpitations |
AF, Heart failure, Shock
|
| GI | ↑ Motility |
Diarrhea, Vomiting, Jaundice
|
| Sweating | Increased |
Profuse
|
| Precipitant | May/May not |
Almost always present
|
SECTION 4: DIAGNOSIS
4.1 CLINICAL DIAGNOSIS
๐จ Thyroid storm is a CLINICAL diagnosis
Do NOT wait for biochemical confirmation to initiate treatment
Diagnostic Approach
SUSPECTED THYROID STORM
โ
โผ
CLINICAL ASSESSMENT
โข Known/Suspected hyperthyroidism
โข Fever > 38.5°C
โข Tachycardia > 140
โข Altered mental status
โข Precipitant present
โ
โผ
CALCULATE BURCH-WARTOFSKY SCORE
โ
โผ
SCORE ≥ 45 = HIGHLY SUGGESTIVE
โ
โผ
INITIATE TREATMENT IMMEDIATELY
โ
โผ
SEND LABS (TFTs, etc.)
BUT DO NOT DELAY TREATMENT
4.2 BURCH-WARTOFSKY POINT SCALE (BWPS)
Scoring System
| Parameter | Criteria | Points |
|
TEMPERATURE
|
||
| 37.2-37.7°C (99-99.9°F) | 5 | |
| 37.8-38.2°C (100-100.9°F) | 10 | |
| 38.3-38.8°C (101-101.9°F) | 15 | |
| 38.9-39.4°C (102-102.9°F) | 20 | |
| 39.4-39.9°C (103-103.9°F) | 25 | |
| ≥ 40°C (≥ 104°F) |
30
|
|
|
HEART RATE
|
||
| 100-109 bpm | 5 | |
| 110-119 bpm | 10 | |
| 120-129 bpm | 15 | |
| 130-139 bpm | 20 | |
| ≥ 140 bpm |
25
|
|
|
ATRIAL FIBRILLATION
|
||
| Absent | 0 | |
| Present |
10
|
|
|
CONGESTIVE HEART FAILURE
|
||
| Absent | 0 | |
| Mild (pedal edema) | 5 | |
| Moderate (bibasal crackles) | 10 | |
| Severe (pulmonary edema) |
15
|
|
|
GI-HEPATIC DYSFUNCTION
|
||
| Absent | 0 | |
| Moderate (diarrhea, nausea, vomiting, abdominal pain) | 10 | |
| Severe (unexplained jaundice) |
20
|
|
|
CNS DISTURBANCE
|
||
| Absent | 0 | |
| Mild (agitation) | 10 | |
| Moderate (delirium, psychosis, extreme lethargy) | 20 | |
| Severe (seizure, coma) |
30
|
|
|
PRECIPITATING EVENT
|
||
| Absent | 0 | |
| Present |
10
|
Interpretation
| Total Score | Interpretation | Action |
|
≥ 45
|
Highly suggestive of thyroid storm
|
๐จ Treat immediately |
|
25-44
|
Impending storm / Probable
|
Treat aggressively; Close monitoring |
|
< 25
|
Storm unlikely
|
Evaluate for other causes |
Score Calculation Example
| Parameter | Finding | Points |
| Temperature | 39.5°C | 25 |
| Heart Rate | 145 bpm | 25 |
| AF | Present | 10 |
| CHF | Moderate | 10 |
| GI | Diarrhea, Nausea | 10 |
| CNS | Delirium | 20 |
| Precipitant | Pneumonia | 10 |
|
TOTAL
|
110
|
Score 110 = Thyroid Storm โ Initiate treatment immediately
4.3 JAPANESE THYROID ASSOCIATION (JTA) CRITERIA
Alternative Diagnostic Criteria
Prerequisites
| Must Have |
| Thyrotoxicosis (elevated FT3 and/or FT4) |
First Combination (TS1)
| Criteria | Required |
| CNS manifestation | โ |
| PLUS Fever ≥ 38°C | โ |
| PLUS ONE of: | |
| โข Tachycardia ≥ 130 | OR |
| โข CHF (NYHA IV or Killip III) | OR |
| โข GI/Hepatic (Nausea/Vomiting/Diarrhea, Bilirubin ≥ 3 mg/dL) |
Second Combination (TS2)
| Criteria | Required |
| At least 3 of the following: | โ |
| โข Fever ≥ 38°C | |
| โข Tachycardia ≥ 130 | |
| โข CHF (NYHA IV or Killip III) | |
| โข GI/Hepatic manifestations |
JTA Grade
| Grade | Definition |
|
TS1
|
Definite thyroid storm |
|
TS2
|
Probable thyroid storm |
4.4 LABORATORY INVESTIGATIONS
Urgent / Immediate
| Test | Expected Finding | Notes |
|
TSH
|
Suppressed (< 0.1) | Confirms thyrotoxicosis |
|
FT4
|
Elevated | May not be markedly elevated |
|
FT3
|
Elevated | May be more elevated than FT4 |
|
CBC
|
Leukocytosis or Normal | Infection; Stress response |
|
LFTs
|
Often elevated | Hepatic dysfunction; Monitor |
|
Renal function
|
May be elevated | Dehydration; Hypoperfusion |
|
Glucose
|
Variable | May be high (stress) or low |
|
Electrolytes
|
Variable | Hyponatremia; Hypokalemia |
|
Calcium
|
May be elevated | ↑ Bone turnover |
|
Cortisol
|
Should be elevated | If low โ adrenal insufficiency |
|
Lactate
|
May be elevated | Hypoperfusion |
|
ABG
|
Variable | Metabolic acidosis (severe) |
|
Coagulation
|
May be deranged | DIC in severe cases |
Additional Investigations
| Test | Purpose |
|
ECG
|
AF, Sinus tachycardia, Ischemia |
|
Chest X-ray
|
Pulmonary edema; Infection |
|
Blood cultures
|
Suspected sepsis |
|
Urine analysis / Culture
|
UTI |
|
Cardiac enzymes
|
If cardiac ischemia suspected |
|
Lumbar puncture
|
If meningitis suspected |
|
CT scan
|
If stroke/other pathology suspected |
4.5 IMPORTANT NOTES ON LABS
| Point |
|
๐ Biochemical severity does NOT correlate with clinical severity
|
| T4/T3 levels in storm may be similar to uncomplicated thyrotoxicosis |
|
Storm is defined by clinical decompensation, not hormone levels
|
|
Do NOT delay treatment waiting for labs
|
| TSH is most reliable (should be suppressed) |
| FT4/FT3 confirm thyrotoxicosis |
4.6 DIFFERENTIAL DIAGNOSIS
| Condition | Distinguishing Features |
|
Sepsis / Septic shock
|
May coexist; Source of infection; Procalcitonin |
|
Malignant hyperthermia
|
Post-anesthesia; Muscle rigidity |
|
Neuroleptic malignant syndrome
|
Neuroleptic use; Rigidity; ↑ CK |
|
Serotonin syndrome
|
Serotonergic drug use; Clonus; Hyperreflexia |
|
Anticholinergic toxicity
|
Dry, flushed skin; Mydriasis; Urinary retention |
|
Drug withdrawal
|
Alcohol, Benzodiazepine |
|
Heat stroke
|
Environmental exposure; Dry skin |
|
Pheochromocytoma crisis
|
Paroxysmal; ↑↑ BP; ↑ Catecholamines |
|
Acute psychosis
|
Primary psychiatric; Normal TFTs |
|
Meningitis / Encephalitis
|
Meningism; CSF abnormal |
SECTION 5: MANAGEMENT โ OVERVIEW
5.1 PRINCIPLES OF MANAGEMENT
| Principle | Goal |
|
๐จ ICU admission
|
Intensive monitoring and support |
|
Block thyroid hormone synthesis
|
Prevent new hormone production |
|
Block thyroid hormone release
|
Prevent release of stored hormone |
|
Block peripheral T4→T3 conversion
|
Reduce active hormone |
|
Block peripheral effects
|
Beta-blockade |
|
Supportive care
|
Fluids, Cooling, Glucose, Oxygen |
|
Treat relative adrenal insufficiency
|
Glucocorticoids |
|
Identify and treat precipitant
|
Infection, etc. |
|
Definitive therapy planning
|
After stabilization |
5.2 TREATMENT ALGORITHM โ OVERVIEW
๐จ THYROID STORM โ EMERGENCY MANAGEMENT
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
STEP 1: ICU ADMISSION & SUPPORTIVE CARE
↓
STEP 2: BLOCK SYNTHESIS (ATD)
↓
STEP 3: BLOCK RELEASE (IODINE) โ 1 HOUR AFTER ATD
↓
STEP 4: BLOCK PERIPHERAL EFFECTS (BETA-BLOCKER)
↓
STEP 5: BLOCK CONVERSION (GLUCOCORTICOIDS)
↓
STEP 6: TREAT PRECIPITANT
↓
STEP 7: ADJUNCTIVE THERAPIES (IF REFRACTORY)
↓
STEP 8: DEFINITIVE THERAPY PLANNING
SECTION 6: MANAGEMENT โ DETAILED
6.1 STEP 1: ICU ADMISSION AND SUPPORTIVE CARE
ICU Admission
| Requirement | Rationale |
|
๐จ Mandatory ICU/HDU admission
|
High mortality; Need for intensive monitoring |
| Continuous cardiac monitoring | Arrhythmias; Hemodynamic instability |
| Frequent vital signs | Every 15-30 minutes initially |
| Arterial line | If hemodynamically unstable |
| Central venous access | Fluid resuscitation; Vasopressors if needed |
| Urinary catheter | Fluid balance monitoring |
Airway and Breathing
| Action | Notes |
| Supplemental oxygen | Maintain SpO2 > 94% |
| Airway protection | If altered consciousness; Aspiration risk |
| Intubation | If respiratory failure; Severe altered consciousness |
| Mechanical ventilation | As needed |
Fluid Resuscitation
| Action | Details |
|
IV access
|
Large bore; Multiple lines if needed |
|
Aggressive IV fluids
|
NS or RL; Correct dehydration |
|
Volume deficit
|
Often 3-5 liters |
|
Dextrose
|
Add D5 if hypoglycemic; High glucose demand |
|
Monitor
|
Urine output; CVP if available |
โ ๏ธ Caution in heart failure โ Balance fluid resuscitation with cardiac status
Temperature Control (Cooling)
| Action | Details |
|
Active cooling
|
Cooling blankets; Ice packs (axilla, groin) |
|
Antipyretics
|
๐ Paracetamol 1 g IV/PO q6h
|
|
โ Avoid Aspirin
|
Displaces T4 from TBG → ↑ Free T4 |
|
Tepid sponging
|
Adjunct |
|
Cool IV fluids
|
May help |
Glucose Management
| Action | Notes |
| Monitor glucose | Frequently |
| Dextrose infusion | High metabolic demand; Risk of hypoglycemia |
| Avoid hyperglycemia | Stress response may cause hyperglycemia initially |
Electrolyte Correction
| Abnormality | Action |
| Hypokalemia | Replace potassium |
| Hyponatremia | Usually dilutional; Fluid restriction if euvolemic |
| Hypocalcemia | Replace if symptomatic |
6.2 STEP 2: BLOCK THYROID HORMONE SYNTHESIS (ATD)
Drug Choice
| Drug | Preference |
|
๐ PTU (Propylthiouracil)
|
โ
Preferred
|
|
๐ Methimazole / Carbimazole
|
Alternative |
Why PTU is Preferred in Thyroid Storm
| Reason |
|
Blocks peripheral T4 to T3 conversion (additional benefit)
|
| Faster onset of action |
| Blocks synthesis + conversion |
PTU Dosing
| Phase | Dose | Route |
|
Loading dose
|
500-1000 mg
|
PO/NG |
|
Maintenance
|
200-250 mg every 4 hours
|
PO/NG |
|
Total daily dose
|
1000-1500 mg/day |
Methimazole / Carbimazole (Alternative)
| Phase | Dose | Route |
|
Loading dose
|
60-80 mg (MMI) or 80-100 mg (Carbimazole)
|
PO/NG |
|
Maintenance
|
20-30 mg every 6-8 hours
|
PO/NG |
Administration
| Route | Notes |
|
Oral
|
If patient can swallow |
|
Nasogastric tube
|
If unable to swallow |
|
Rectal
|
PTU can be given rectally (enema) if no other route |
|
โ No IV formulation
|
ATDs only available PO |
India Availability
| Drug | Availability |
|
Carbimazole
|
Widely available (Neomercazole 5mg, 10mg, 20mg) |
|
PTU
|
Available (50mg tablets) |
|
Methimazole
|
Available |
6.3 STEP 3: BLOCK THYROID HORMONE RELEASE (IODINE)
Timing
๐จ CRITICAL: Give iodine at least 1 HOUR AFTER ATD
Rationale
| Why Wait 1 Hour? |
| Iodine can initially ↑ thyroid hormone synthesis (Jod-Basedow) |
| ATD must block synthesis FIRST |
| Then iodine blocks RELEASE of preformed hormone (Wolff-Chaikoff effect) |
| Giving iodine first can WORSEN thyroid storm |
Iodine Options
| Drug | Dose | Frequency | Route |
|
๐ Lugolโs Iodine (Strong Iodine Solution)
|
4-8 drops
|
Every 6-8 hours | PO/NG |
|
๐ SSKI (Saturated Solution of Potassium Iodide)
|
5 drops
|
Every 6 hours | PO/NG |
|
๐ Sodium Iodide
|
500 mg-1 g
|
Every 8-12 hours | IV |
|
๐ Potassium Iodide tablets
|
60 mg
|
Every 6-8 hours | PO |
|
๐ Ipodate/Iopanoic acid
|
500 mg
|
Every 12 hours | PO |
Lugolโs Iodine
| Composition |
| 5% Iodine + 10% Potassium Iodide |
| ~8 mg iodine per drop |
| Dilute in water or juice (bitter taste) |
SSKI
| Composition |
| Saturated Potassium Iodide |
| ~50 mg iodine per drop |
| Fewer drops needed |
If Iodine Allergic
| Alternative | Dose |
|
๐ Lithium Carbonate
|
300 mg every 8 hours PO
|
Lithium
| Notes |
| Blocks thyroid hormone release |
| Alternative to iodine in allergic patients |
| Monitor lithium levels (target 0.6-1.0 mEq/L) |
| Risk of toxicity |
India Availability
| Drug | Availability |
|
Lugolโs Iodine
|
Available; Pharmacies |
|
SSKI
|
Available |
|
Sodium Iodide IV
|
May be limited |
|
Lithium
|
Available |
6.4 STEP 4: BLOCK PERIPHERAL EFFECTS (BETA-BLOCKERS)
Role
| Effect |
| Control tachycardia |
| Reduce tremor |
| Reduce agitation |
| ↓ Peripheral T4 to T3 conversion (Propranolol) |
| ↓ Catecholamine effects |
Drug Choice
| Drug | Dose | Route | Notes |
|
๐ Propranolol
|
60-80 mg
|
Every 4-6 hours PO | โ Preferred (blocks T4→T3) |
|
๐ Propranolol IV
|
0.5-1 mg
|
Every 5-10 min; Max 10 mg | Severe/Unable to take PO |
|
๐ Esmolol
|
50-100 μg/kg/min
|
IV infusion | Titratable; Short-acting |
|
๐ Metoprolol
|
5 mg
|
IV every 5 min; Max 15 mg | Alternative |
|
๐ Atenolol
|
50-100 mg
|
PO daily | Less preferred (no T4→T3 block) |
Propranolol โ Preferred
| Advantage |
| Non-selective beta-blocker |
| Blocks peripheral T4 to T3 conversion |
| Controls tachycardia and tremor |
| Anxiolytic effect |
Esmolol โ When to Use
| Indication |
| Severe tachycardia with hemodynamic instability |
| Need for rapid titration |
| Uncertain cardiac function |
| Short half-life (can be stopped quickly if problems) |
Dosing in Severe Cases
| Propranolol | Dose |
|
IV loading
|
0.5-1 mg slow IV every 5-10 min until HR controlled |
|
Maintenance
|
Oral 60-80 mg every 4-6 hours |
|
May need higher doses
|
Up to 120 mg every 6 hours |
Contraindications / Caution
| Contraindication | Alternative |
|
โ Severe bronchospasm / Asthma
|
Diltiazem or Verapamil |
|
โ ๏ธ Decompensated heart failure
|
Use with extreme caution; Esmolol preferred |
|
โ ๏ธ Hypotension
|
Cautious use; May need vasopressors |
If Beta-Blocker Contraindicated
| Alternative | Dose |
|
๐ Diltiazem
|
60-90 mg PO q6h; or 0.25 mg/kg IV bolus then 5-15 mg/hr |
|
๐ Verapamil
|
40-80 mg PO TID |
6.5 STEP 5: BLOCK PERIPHERAL CONVERSION + ADRENAL SUPPORT (GLUCOCORTICOIDS)
Role
| Effect |
| ↓ Peripheral T4 to T3 conversion |
| Treat relative adrenal insufficiency |
| Anti-inflammatory |
| Possible direct thyroid effect |
Rationale for Glucocorticoids
| Point |
| Thyroid hormone ↑ cortisol metabolism |
| Severe thyrotoxicosis depletes adrenal reserve |
| Relative adrenal insufficiency is common |
| Glucocorticoids improve outcomes |
Drug Options
| Drug | Dose | Route | Frequency |
|
๐ Hydrocortisone
|
100 mg
|
IV | Every 8 hours |
|
๐ Dexamethasone
|
2 mg
|
IV | Every 6 hours |
|
๐ Methylprednisolone
|
60-80 mg
|
IV | Every 8-12 hours |
Preference
| Drug | Notes |
|
Hydrocortisone
|
โ Preferred; Mineralocorticoid activity; Stress dose |
|
Dexamethasone
|
More potent T4→T3 inhibition; No mineralocorticoid |
Duration
| Phase | Duration |
|
Acute
|
Continue until clinically stable |
|
Taper
|
Over days as patient improves |
|
Discontinue
|
Once stable; Adrenal function recovers |
6.6 STEP 6: TREAT THE PRECIPITANT
Identify and Treat
| Precipitant | Action |
|
Infection
|
Empiric broad-spectrum antibiotics; Cultures; Source control |
|
Surgery
|
Supportive; Was patient prepared? |
|
MI
|
Cardiology; Careful with beta-blockers in acute setting |
|
DKA
|
Standard DKA protocol |
|
Stroke
|
Neurology; Supportive |
|
Trauma
|
Trauma management |
|
Drug-related
|
Discontinue offending agent if possible |
Infection โ Most Common
| Action |
| Blood cultures before antibiotics |
| Chest X-ray |
| Urine analysis and culture |
| Empiric antibiotics (Broad-spectrum) |
| Adjust based on culture results |
6.7 STEP 7: ADJUNCTIVE THERAPIES (REFRACTORY CASES)
Cholestyramine
| Drug |
๐ Cholestyramine
|
|
Dose
|
4 g every 6 hours PO |
|
Mechanism
|
Binds thyroid hormone in gut; ↓ Enterohepatic circulation |
|
Use
|
Adjunct in refractory cases |
Plasmapheresis / Plasma Exchange
| Indication |
| Refractory thyroid storm |
| Rapidly deteriorating despite medical therapy |
| Pre-operative preparation for emergency thyroidectomy |
| Mechanism |
| Removes circulating thyroid hormones |
| Removes TRAb |
| Temporary effect |
| Availability |
| Major centers |
| ๐ฎ๐ณ Available in tertiary hospitals in India |
Emergency Thyroidectomy
| Indication |
| Refractory to all medical therapy |
| Patient continues to deteriorate |
| Pre-operative optimization critical |
| Notes |
| Very high-risk surgery |
| Should be performed by experienced thyroid surgeon |
| Requires maximal medical optimization first |
| Mortality high but may be life-saving |
SECTION 7: TREATMENT SUMMARY TABLE
7.1 TREATMENT AT A GLANCE
| Step | Agent | Dose | Route | Timing |
|
1
|
Supportive Care
|
ICU; Fluids; Cooling; O2 | Immediate | |
|
2
|
๐ PTU
|
500-1000 mg load, then 200-250 mg q4h | PO/NG | Immediate |
|
OR ๐ Methimazole
|
60-80 mg load, then 20-30 mg q6-8h | PO/NG | ||
|
3
|
๐ Lugolโs Iodine
|
4-8 drops q6-8h | PO/NG |
1 hour AFTER ATD
|
|
OR ๐ SSKI
|
5 drops q6h | PO/NG | ||
|
OR ๐ Lithium (if iodine allergic)
|
300 mg q8h | PO | ||
|
4
|
๐ Propranolol
|
60-80 mg q4-6h PO; or 0.5-1 mg IV q5-10min | PO/IV | Immediate |
|
OR ๐ Esmolol
|
50-100 μg/kg/min | IV infusion | ||
|
5
|
๐ Hydrocortisone
|
100 mg q8h | IV | Immediate |
|
OR ๐ Dexamethasone
|
2 mg q6h | IV | ||
|
6
|
Treat Precipitant
|
Antibiotics; etc. | Immediate | |
|
7
|
๐ Cholestyramine (adjunct)
|
4 g q6h | PO | If refractory |
|
Plasmapheresis
|
If refractory | |||
|
8
|
๐ Paracetamol
|
1 g q6h | PO/IV | For fever |
|
โ Avoid Aspirin
|
7.2 ORDER OF ADMINISTRATION
TIME 0: ICU Admission + Supportive Care
โ
โโโ IV fluids
โโโ Oxygen
โโโ Cooling (Paracetamol, NOT Aspirin)
โโโ Cardiac monitoring
โ
โผ
TIME 0: ๐ PTU 500-1000 mg (or MMI 60-80 mg)
๐ Propranolol 60-80 mg (or IV if severe)
๐ Hydrocortisone 100 mg IV
โ
โผ
TIME +1 HR: ๐ Lugol's Iodine 4-8 drops (or SSKI 5 drops)
โ
โผ
TIME +4 HR: ๐ PTU 200-250 mg (repeat q4h)
โ
โผ
ONGOING: Continue all medications as scheduled
Monitor and adjust
Treat precipitant
SECTION 8: MONITORING
8.1 CLINICAL MONITORING
| Parameter | Frequency | Target/Notes |
|
Heart rate
|
Continuous | Target < 100 bpm |
|
Blood pressure
|
Every 15-30 min initially | Avoid hypotension |
|
Temperature
|
Every 1-2 hours | Target < 38°C |
|
Respiratory rate
|
Continuous | Watch for respiratory failure |
|
SpO2
|
Continuous | > 94% |
|
Mental status
|
Hourly | Improvement expected |
|
Urine output
|
Hourly | > 0.5 mL/kg/hr |
|
Cardiac rhythm
|
Continuous | Watch for AF, Arrhythmias |
8.2 LABORATORY MONITORING
| Test | Frequency | Notes |
|
FT4, FT3, TSH
|
Every 24-48 hours initially | Monitor response |
|
CBC
|
Daily | Agranulocytosis risk with ATD |
|
LFTs
|
Daily | Hepatic dysfunction; ATD toxicity |
|
Renal function
|
Daily | Hypoperfusion |
|
Electrolytes
|
Every 6-12 hours initially | Correct abnormalities |
|
Glucose
|
Every 4-6 hours | Hypo/Hyperglycemia |
|
Lactate
|
As needed | Tissue perfusion |
|
ABG
|
As needed | Acid-base status |
|
Cortisol
|
If adrenal insufficiency suspected |
8.3 RESPONSE TO TREATMENT
Expected Timeline
| Timeframe | Expected Response |
|
Hours
|
↓ Heart rate; ↓ Temperature; ↓ Agitation |
|
24-48 hours
|
Clinical improvement; ↓ FT4/FT3 begins |
|
3-5 days
|
Significant clinical improvement |
|
1-2 weeks
|
Near euthyroid; Stable |
Signs of Improvement
| Parameter | Expected Change |
| Temperature | Normalizing |
| Heart rate | < 100 bpm |
| Mental status | Improving |
| Cardiac function | Stabilizing |
| FT4/FT3 | Decreasing |
Signs of Deterioration
| ๐จ Warning Signs |
| Persistent hyperthermia |
| Worsening altered consciousness |
| Refractory tachycardia |
| Cardiovascular collapse |
| Multi-organ failure |
| Worsening jaundice |
SECTION 9: COMPLICATIONS
9.1 COMPLICATIONS OF THYROID STORM
| Complication | Management |
|
Cardiovascular collapse / Shock
|
Vasopressors; Inotropes; Fluid resuscitation |
|
Atrial fibrillation
|
Rate control (Beta-blockers); Anticoagulation |
|
Heart failure
|
Diuretics; Inotropes; Cautious beta-blockers |
|
Respiratory failure
|
Intubation; Mechanical ventilation |
|
Multi-organ failure
|
ICU supportive care |
|
DIC
|
Supportive; Blood products |
|
Seizures
|
Benzodiazepines; Phenytoin |
|
Rhabdomyolysis
|
IV fluids; Monitor CK |
|
Coma
|
Supportive; Airway protection |
|
Death
|
Despite treatment in 10-30% |
9.2 COMPLICATIONS OF TREATMENT
| Complication | Cause | Management |
|
Agranulocytosis
|
ATD (PTU/MMI) | Stop ATD; G-CSF; Antibiotics |
|
Hepatotoxicity
|
ATD (especially PTU) | Stop ATD; Supportive |
|
Hypotension
|
Beta-blockers | Reduce dose; Vasopressors |
|
Bradycardia
|
Beta-blockers | Reduce dose; Atropine if severe |
|
Bronchospasm
|
Beta-blockers | Stop; Use CCB alternative |
|
Heart failure worsening
|
Beta-blockers | Careful titration; Esmolol |
|
Iodine allergy
|
Lugolโs/SSKI | Use Lithium instead |
SECTION 10: SPECIAL SITUATIONS
10.1 THYROID STORM IN PREGNANCY
Challenges
| Challenge |
| Diagnosis may be difficult (pregnancy changes TFTs) |
| Fetal considerations |
| Drug safety |
| Higher morbidity and mortality |
Treatment Modifications
| Agent | Recommendation |
|
PTU
|
โ Preferred ATD in pregnancy (especially 1st trimester) |
|
Methimazole
|
Avoid in 1st trimester (teratogenic) |
|
Propranolol
|
Use with caution; Monitor fetus |
|
Iodine
|
Can be used |
|
Glucocorticoids
|
Can be used |
|
Cooling
|
Avoid hyperthermia (fetal risk) |
Delivery
| Consideration |
| May need emergency delivery if mother unstable |
| Neonatal thyrotoxicosis possible |
| Multidisciplinary team (Endocrine, OB, Neonatal) |
10.2 THYROID STORM POST-RAI
Features
| Point |
| Rare complication of RAI therapy |
| Usually within 1-2 weeks of RAI |
| Due to release of stored hormone from damaged thyroid |
| More common in inadequately prepared patients |
Prevention
| Measure |
| Pre-treat with ATD (especially if severe thyrotoxicosis) |
| Avoid RAI in severe uncontrolled disease |
| Ensure adequate preparation |
10.3 THYROID STORM WITH ATRIAL FIBRILLATION
Management
| Issue | Management |
|
Rate control
|
Beta-blockers (Propranolol, Esmolol); Digoxin less effective in thyrotoxicosis |
|
Anticoagulation
|
↑ Stroke risk; Consider anticoagulation |
|
Cardioversion
|
Often reverts spontaneously once euthyroid; May need if hemodynamically unstable |
|
Warfarin sensitivity
|
Thyrotoxic patients metabolize vitamin K factors faster; Lower warfarin dose needed |
10.4 THYROID STORM WITH HEART FAILURE
Challenge
| Point |
| Beta-blockers can worsen heart failure |
| Heart failure is from hyperthyroidism itself |
| Treating thyrotoxicosis improves heart failure |
Management
| Approach |
|
Esmolol โ Short-acting; Can be stopped quickly
|
| Start with very low doses |
| Titrate carefully |
| Inotropic support if needed |
| Diuretics for pulmonary edema |
| Digoxin less effective (increased clearance) |
10.5 AMIODARONE-INDUCED THYROID STORM
Challenges
| Point |
| May be AIT-1 (excess iodine) or AIT-2 (thyroiditis) or Mixed |
| Amiodarone has very long half-life (weeks-months) |
| Stopping amiodarone may not be feasible (cardiac indication) |
Treatment
| Type | Treatment |
|
AIT-1
|
ATD (high dose) + Potassium perchlorate |
|
AIT-2
|
Glucocorticoids |
|
Mixed/Unknown
|
Combined ATD + Glucocorticoids |
|
Refractory
|
Emergency thyroidectomy; Plasmapheresis |
Potassium Perchlorate
| Drug |
๐ Potassium Perchlorate
|
|
Dose
|
250 mg every 6 hours (1 g/day) |
|
Duration
|
2-4 weeks maximum |
|
Mechanism
|
Blocks iodine uptake into thyroid |
|
Availability
|
Limited; May need to compound ๐ฎ๐ณ |
SECTION 11: DEFINITIVE THERAPY AFTER STABILIZATION
11.1 TIMING
| Point |
| Definitive therapy after patient stabilized |
| Continue ATD until decision made |
| Discuss options with patient |
| Consider cause (Gravesโ vs Nodular disease) |
11.2 OPTIONS
| Option | Notes |
|
Continue ATD
|
12-18 months for Gravesโ (remission possible); Indefinite for nodular disease |
|
Radioactive Iodine (RAI)
|
Definitive; After stabilization; Pre-treat with ATD |
|
Surgery (Thyroidectomy)
|
Definitive; After stabilization; Pre-operative preparation essential |
11.3 RECOMMENDATIONS
| Cause | Preferred Definitive Therapy |
|
Gravesโ disease
|
RAI or Surgery (avoid recurrence of storm) |
|
Toxic MNG
|
Surgery or RAI |
|
Toxic adenoma
|
Surgery or RAI |
|
AIT
|
Thyroidectomy if refractory/recurrent |
SECTION 12: PREVENTION
12.1 PREVENTION STRATEGIES
Primary Prevention
| Strategy |
| Early diagnosis and treatment of hyperthyroidism |
| Patient education on compliance |
| Regular follow-up |
| Avoid RAI in severe uncontrolled disease without preparation |
Pre-Operative Preparation
| Before Thyroid Surgery |
| Achieve euthyroid state with ATD |
| Add Lugolโs iodine for 7-10 days pre-op |
| Beta-blocker for heart rate control |
| Do NOT operate on unprepared thyrotoxic patient |
Before RAI
| Preparation |
| Pre-treat severe cases with ATD |
| Ensure not profoundly thyrotoxic |
| Stop ATD 3-7 days before RAI |
| Resume ATD if persistent hyperthyroidism post-RAI |
Patient Education
| Educate Patient On |
| Importance of medication compliance |
| Warning signs of worsening |
| When to seek medical attention |
| Avoiding precipitants |
SECTION 13: INDIA-SPECIFIC CONSIDERATIONS
13.1 EPIDEMIOLOGY IN INDIA
| Point |
| Gravesโ disease most common cause |
| Delayed presentation common |
| Infection most common precipitant |
| TB and tropical infections may trigger |
| Non-compliance due to cost/access |
13.3 HEALTHCARE SETTING CONSIDERATIONS
Tertiary/Teaching Hospital
| Resource | Availability |
| ICU | โ |
| Endocrinology | โ |
| Thyroid surgery | โ |
| Plasmapheresis | โ |
| RAI | โ |
District Hospital
| Resource | Availability |
| ICU | Variable |
| Endocrinology | May need referral |
| Thyroid surgery | May need referral |
| Plasmapheresis | โ |
| Basic drugs | โ |
Primary Health Center
| Action |
| Recognize thyroid storm |
| Initiate supportive care |
| Start available medications |
|
REFER IMMEDIATELY to higher center
|
13.4 PRACTICAL TIPS FOR INDIAN SETTING
| Tip |
|
Lugolโs iodine widely available โ use it
|
|
Carbimazole can be used if PTU unavailable (higher doses)
|
|
Propranolol effective and affordable
|
|
Hydrocortisone available in most hospitals
|
|
Donโt delay treatment โ Start whatโs available
|
|
Refer early to tertiary center if not responding
|
|
Screen for TB as precipitant
|
|
Empiric antibiotics for suspected infection
|
SECTION 14: SUMMARY TABLES
14.1 BURCH-WARTOFSKY SCORE โ QUICK REFERENCE
| Parameter | Score Range |
| Temperature | 5-30 |
| Heart rate | 5-25 |
| Atrial fibrillation | 0-10 |
| Heart failure | 0-15 |
| GI-Hepatic | 0-20 |
| CNS | 0-30 |
| Precipitant | 0-10 |
|
TOTAL
|
0-140
|
| Score | Interpretation |
| ≥ 45 | Thyroid storm |
| 25-44 | Impending storm |
| < 25 | Storm unlikely |
14.2 DRUG DOSES โ QUICK REFERENCE
| Drug | Dose |
|
PTU
|
500-1000 mg load → 200-250 mg q4h |
|
Methimazole
|
60-80 mg load → 20-30 mg q6-8h |
|
Lugolโs Iodine
|
4-8 drops q6-8h (1 hr AFTER ATD) |
|
SSKI
|
5 drops q6h |
|
Propranolol PO
|
60-80 mg q4-6h |
|
Propranolol IV
|
0.5-1 mg q5-10min (max 10 mg) |
|
Esmolol
|
50-100 μg/kg/min |
|
Hydrocortisone
|
100 mg IV q8h |
|
Dexamethasone
|
2 mg IV q6h |
|
Cholestyramine
|
4 g q6h |
|
Lithium
|
300 mg q8h (if iodine allergic) |
|
Paracetamol
|
1 g q6h (for fever) |
14.3 TREATMENT SEQUENCE
| Step | Time | Action |
| 1 | 0 | ICU; IV fluids; Cooling; O2; Monitoring |
| 2 | 0 | PTU 500-1000 mg (or MMI 60-80 mg) |
| 3 | 0 | Propranolol 60-80 mg PO (or IV if severe) |
| 4 | 0 | Hydrocortisone 100 mg IV |
| 5 | 0 | Identify and treat precipitant |
| 6 | +1 hr | Lugolโs iodine 4-8 drops |
| 7 | +4 hr | PTU 200-250 mg (continue q4h) |
| 8 | Ongoing | Monitor; Adjust; Supportive care |
14.4 MONITORING CHECKLIST
| Parameter | Frequency |
| Heart rate | Continuous |
| Blood pressure | q15-30min |
| Temperature | q1-2h |
| SpO2 | Continuous |
| Mental status | q1h |
| Urine output | q1h |
| TFTs | q24-48h |
| CBC, LFTs, Renal | Daily |
| Electrolytes, Glucose | q6-12h |
14.5 CONTRAINDICATIONS SUMMARY
| โ AVOID |
|
Aspirin โ Displaces T4 from TBG
|
|
Iodine BEFORE ATD โ Worsens thyrotoxicosis
|
|
Beta-blockers in severe asthma โ Bronchospasm
|
|
Aggressive beta-blockade in decompensated HF โ Cardiogenic shock
|
|
Delay in treatment โ Increased mortality
|
14.6 WHEN TO ESCALATE
| ๐จ Escalate If |
| No improvement in 24-48 hours |
| Worsening vital signs |
| Deteriorating mental status |
| Developing multi-organ failure |
| Refractory hyperthermia |
| Consider: Plasmapheresis, Emergency thyroidectomy |
๐ ABBREVIATIONS
| Abbreviation | Full Form |
| ABG | Arterial Blood Gas |
| AF | Atrial Fibrillation |
| AIT | Amiodarone-Induced Thyrotoxicosis |
| ATD | Antithyroid Drug |
| BWPS | Burch-Wartofsky Point Scale |
| CBC | Complete Blood Count |
| CHF | Congestive Heart Failure |
| CK | Creatine Kinase |
| CNS | Central Nervous System |
| CVP | Central Venous Pressure |
| DIC | Disseminated Intravascular Coagulation |
| DKA | Diabetic Ketoacidosis |
| FT3 | Free Triiodothyronine |
| FT4 | Free Thyroxine |
| G-CSF | Granulocyte Colony-Stimulating Factor |
| GI | Gastrointestinal |
| HDU | High Dependency Unit |
| HR | Heart Rate |
| ICU | Intensive Care Unit |
| IV | Intravenous |
| JTA | Japanese Thyroid Association |
| LFT | Liver Function Tests |
| MI | Myocardial Infarction |
| MMI | Methimazole |
| MNG | Multinodular Goiter |
| NG | Nasogastric |
| NS | Normal Saline |
| NYHA | New York Heart Association |
| PO | Per Oral |
| PTU | Propylthiouracil |
| RAI | Radioactive Iodine |
| RL | Ringerโs Lactate |
| SSKI | Saturated Solution of Potassium Iodide |
| T3 | Triiodothyronine |
| T4 | Thyroxine |
| TB | Tuberculosis |
| TBG | Thyroxine-Binding Globulin |
| TFT | Thyroid Function Tests |
| TRAb | TSH Receptor Antibodies |
| TSH | Thyroid-Stimulating Hormone |
| UTI | Urinary Tract Infection |
๐ REFERENCES
| Source | Year |
| Burch HB, Wartofsky L. Life-threatening thyrotoxicosis. Endocrinol Metab Clin North Am | 1993 |
| Akamizu T et al. Diagnostic criteria for thyroid storm. Thyroid | 2012 |
| Ross DS et al. ATA Guidelines for Hyperthyroidism. Thyroid | 2016 |
| Chiha M et al. Thyroid storm: An updated review. J Intensive Care Med | 2015 |
| Angell TE et al. Thyroid Storm. Endotext | 2022 |
| Swee du S et al. Clinical review: Thyroid storm. Crit Care | 2015 |
| Harrisonโs Principles of Internal Medicine | 21st Edition |
| Williams Textbook of Endocrinology | 14th Edition |
| Indian Thyroid Society Guidelines | Various |
Document Version: 1.0
Last Updated: December 2025
For: Healthcare Professionals Only โ Emergency Medicine, Critical Care, Endocrinology
๐จ EMERGENCY DOCUMENT โ Quick reference for life-threatening condition
Disclaimer: Clinical judgment must be exercised for individual patients. This guideline is for educational purposes. Local protocols should be followed. Mortality is 10-30% even with optimal treatment โ Early recognition and aggressive management are critical.
End of Guideline
๐ก๏ธ
Medical Advisory
Clinical guidelines are subject to change. Physicians should exercise their regular clinical judgment. This protocol does not replace individual institutional policies. Verified for Q1 2026.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.